Affordable Prescriptions for Patients Act of 2023
1 agreed to
| Amendment | Sponsor | Status |
|---|---|---|
| SAMDT 2,399 | Cornyn, John | Agreed to |
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Affordable Prescriptions for Patients Act of 2023
This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.
Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
Held at the desk.
- Engrossed in Senate Formatted Text PDF Formatted XML
- Introduced in Senate Formatted Text PDF Formatted XML
- Reported to Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 150: Affordable Prescriptions for Patients Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-150/
"S. 150: Affordable Prescriptions for Patients Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-150/.
S. 150, 118th Cong. (2026), https://openamerica.io/bill/118-S-150/.
[S. 150: Affordable Prescriptions for Patients Act of 2023](https://openamerica.io/bill/118-S-150/)